Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Petros Pharmaceuticals, Inc.PTPI · Entity 8730 | Chief Financial Officer | December 01, 2020 | December 04, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Petros Pharmaceuticals, Inc.
Report date December 01, 2020 · Filed December 04, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.0001 per shareSEC Table I · non-derivative | IndirectBy Metuchen Therapeutics, LLC | 975 |
Reported balance
After 2020-12-01 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2020-12-01 · Grant · Acquired 975 · Balance 975 F1: Received in exchange for 1964.29 units of Metuchen Pharmaceuticals, LLC ("Metuchen") in connection with the merger (the "Merger") of Metuchen into Petros Pharmaceuticals, Inc. ("Petros"). Mr. Lavan's holding of units of Metuchen was on a look-through basis based on proportionate ownership of Metuchen Therapeutics, LLC, which owned 550,000 units of Metuchen. On the effective date of the Merger, the closing price of Petros was $3.99 per share. |
Filing footnotes · ownership attribution and instrument terms
F1: Received in exchange for 1964.29 units of Metuchen Pharmaceuticals, LLC ("Metuchen") in connection with the merger (the "Merger") of Metuchen into Petros Pharmaceuticals, Inc. ("Petros"). Mr. Lavan's holding of units of Metuchen was on a look-through basis based on proportionate ownership of Metuchen Therapeutics, LLC, which owned 550,000 units of Metuchen. On the effective date of the Merger, the closing price of Petros was $3.99 per share.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 01, 2020 Filed Dec 4, 2020 02:58 UTC | Petros Pharmaceuticals, Inc. PTPI · Entity 8730 | GrantCommon Stock, par value $0.0001 per share | 975 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-20-020631 · doc1.xml · nonDerivative · entry 1 Lavan Keith · CIK 0001833345 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Metuchen Therapeutics, LLC Disclosed balance after: 975 F1 · price: Received in exchange for 1964.29 units of Metuchen Pharmaceuticals, LLC ("Metuchen") in connection with the merger (the "Merger") of Metuchen into Petros Pharmaceuticals, Inc. ("Petros"). Mr. Lavan's holding of units of Metuchen was on a look-through basis based on proportionate ownership of Metuchen Therapeutics, LLC, which owned 550,000 units of Metuchen. On the effective date of the Merger, the closing price of Petros was $3.99 per share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.